Beijing Hotgen Biotech Co., Ltd.'s (SHSE:688068) Market Cap Dropped CN¥370m Last Week; Retail Investors Bore the Brunt

Key Insights Beijing Hotgen Biotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 44% of the business is held by the

Simply Wall StApr 17 12:51

Hejing Biotech (688068.SH): A total cost of 92.06 million yuan to buy back 3.14% of the shares

Gelonghui, April 16, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on April 15, 2024, the company had repurchased 2,893,010 shares through centralized bidding transactions, accounting for 3.14% of the company's total share capital. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 92,016,460.62 (excluding transaction fees such as stamp duty and transaction commissions).

Gelonghui FinanceApr 16 17:07

Splice up the IVD business layout! Hot Scene Biotech “went around the corner” to buy back the former upstream subsidiary

① After acquiring Kaijing Gene, Hejing Biotech rearranged the complete industrial chain from upstream key bioactive ingredients for in vitro diagnosis to R&D, production, and sales of reagents and instruments; ② “In the future, we will also create more business for Kaijing Gene, and revenue and profits are expected to continue to grow.”

cls.cnApr 16 15:43

Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan

Beijing Hotgen Biotech (SHA:688068) plans to acquire Beijing Kaijing Gene Technology from affiliated company Beijing Shunjing Biomedical Technology for 11 million yuan, according to the company's disc

MT NewswiresApr 16 12:41

Hejing Biotech (688068.SH) plans to acquire 100% of Kaijing Gene's shares to integrate the in vitro diagnostic business

According to Zhitong Finance App News, Hot View Biotech (688068.SH) announced that in order to integrate the in vitro diagnosis business of the company and related companies, the company plans to acquire 100% of the shares of Beijing Kaijing Gene Technology Co., Ltd. (“Shunjing Gene”) held by the affiliated company Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”). The transfer price for this transaction was 11 million yuan, all of which were paid in cash. According to reports, Kaijing Gene was founded in 2016 and is a biotechnology service company specializing in R&D, production and sales of in vitro diagnostic reagent raw materials. It is proposed for in vitro diagnostic reagent manufacturers

Zhitong FinanceApr 15 17:23

Hot View Biotech (688068.SH): Foreign trade is currently progressing well

Gelonghui, April 11, 丨 Hot View Biotech (688068.SH) Investor Relations Activity Record Sheet shows that the company has always insisted on placing equal emphasis on domestic and foreign markets and is actively expanding overseas markets. Currently, foreign trade is progressing well. The company has established two professional marketing management teams, international and domestic, and has set up subsidiaries in India, Hong Kong and the United States, and set up offices in Thailand to develop global business.

Gelonghui FinanceApr 11 15:49